The bivariate NRIP1/ZEB2 RNA marker permits non-invasive presymptomatic screening of pre-eclampsia

Sci Rep. 2020 Dec 14;10(1):21857. doi: 10.1038/s41598-020-79008-4.

Abstract

Using genome-wide transcriptome analysis by RNA sequencing of first trimester plasma RNA, we tested whether the identification of pregnancies at risk of developing pre-eclampsia with or without preterm birth or growth restriction is possible between weeks 9-14, prior to the appearance of clinical symptoms. We implemented a metaheuristic approach in the self-learning SVM algorithm for differential gene expression analysis of normal pregnancies (n = 108), affected pregnancies (n = 34) and non-pregnant controls (n = 19). Presymptomatic candidate markers for affected pregnancies were validated by RT-qPCR in first trimester samples (n = 34) from an independent cohort. PRKG1 was significantly downregulated in a subset of pregnancies with birth weights below the 10thpercentile as shared symptom. The NRIP1/ZEB2 ratio was found to be upregulated in pregnancies with pre-eclampsia or trisomy 21. Complementary quantitative analysis of both the linear and circular forms of NRIP1 permitted discrimination between pre-eclampsia and trisomy 21. Pre-eclamptic pregnancies showed an increase in linear NRIP1 compared to circular NRIP1, while trisomy 21 pregnancies did not.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood
  • Female
  • Humans
  • Nuclear Receptor Interacting Protein 1 / blood*
  • Pre-Eclampsia / blood*
  • Pregnancy
  • Prospective Studies
  • RNA, Messenger / blood*
  • Up-Regulation*
  • Zinc Finger E-box Binding Homeobox 2 / blood*

Substances

  • Biomarkers
  • NRIP1 protein, human
  • Nuclear Receptor Interacting Protein 1
  • RNA, Messenger
  • ZEB2 protein, human
  • Zinc Finger E-box Binding Homeobox 2